Ildong Pharmaceutical Co., Ltd.
249420.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$441.74B
Close$
$20515.64
55% upside
Current Fair Value
55% upsideUndervalued by 55% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $441.74 Billion |
|---|---|
| Enterprise Value | $535.70 Billion |
| Dividend Yield | $200.00 (1.43%) |
| Earnings per Share | $942.08 |
| Beta | 0.85 |
| Outstanding Shares | 31,482,000 |
Return
| Return on Equity | 16.91% |
|---|---|
| Return on Assets | 7.78% |
| Return on Invested Capital | -8.06% |
Valuation & Multiples
| P/E Ratio | 9.89 |
|---|---|
| PEG | -3.41 |
| Price to Sales | 0.72 |
| Price to Book Ratio | 1.67 |
| Enterprise Value to Revenue | 0.92 |
| Enterprise Value to EBIT | -19.42 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 0.28 |
| Debt to Equity | 0.57 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$149.80 B
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$153.70 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Ildong Pharmaceutical Co., Ltd.
1,104 employees
CEO: Yun Paul Woongsup Ildong Pharmaceutical Co., Ltd., established in 1941 and headquartered in Seoul, South Korea, is a company dedicated to the development, production, and distribution of a wide array of pharmaceutical products. Its extensive portfolio inc...